This is a summary of the European public assessment report (EPAR) for Exforge. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Exforge.
Therapeutic Indication
### Therapeutic indication Treatment of essential hypertension. Exforge is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.
Therapeutic Area (MeSH)
ATC Code
C09DB01
ATC Item
valsartan and amlodipine
Pharmacotherapeutic Group
Agents acting on the renin-angiotensin system
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| valsartan | N/A | 缬沙坦 |
| amlodipine (as amlodipine besilate) | N/A | amlodipine (as amlodipine besilate) |
EMA Name
Exforge
Medicine Name
Exforge
Aliases
N/ANo risk management plan link.
